A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR

Table 1 Patient profiles and results of the present study

Patient No.	Age (year)	Gender	Serum ALT (IU/L)	HBs Ag	HBe Ag	Serum HBV DNA (IU/mL)	PSAD + RCA + IS-PCR detect HBVcccDNA	Note
CHB
1	0-10	M	89	+	+	1.33× 10⁷	+	Figure 2
2	21-30	M	68	+	+	1.46× 10²	+
3	21-30	M	22	+	+	3.595× 10²	+
4	21-30	M	197	+	-	7.51× 10⁴	+
5	11-20	M	21	+	+	3.54× 10⁸	+
6	11-20	M	13	+	+	1.51× 10³	-
7	50-60	M	45	+	-	1.2× 10⁵	-
8	50-60	M	263	+	+	2.73× 10⁵	+
9	20-30	F	54	+	-	3.03× 10⁴	-
10	20-30	F	381	+	+	4.75× 10⁷	+
LC
1	40-50	M	20	+	-	5.13× 10⁷	+	Figure 3
2	40-50	M	58	+	-	1.509× 10⁴	+
3	40-50	M	33	+	-	1.17× 10³	+
4	50-60	M	25	+	+	4.542× 10³	+
5	50-60	M	136	+	-	3.08× 10²	-
6	40-50	F	44	+	+	U.D.	-
HCC
1	30-40	M	55	+	-	U.D.	+	Figure 4
2	40-50	M	47	+	-	U.D.	+
3	40-50	M	12	+	-	2.829× 10²	-
4	40-50	M	44	+	-	2.446× 10⁶	+
5	50-60	F	25	+	+	2.182× 10⁴	+
6	50-60	M	14	+	-	1.11× 10³	+
7	60-70	M	88	+	+	1.79× 10³	+
8	60-70	M	17	-	-	U.D.	+
9	40-50	F	35	+	-	4.464× 10³	-
10	30-40	M	206	+	-	4.44× 10	+

M, male; F, female; U.D., undetected; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; PSAD, plasmid-safe ATP-dependent DNase; RCA, rolling circle amplification; IS-PCR, situ polymerase chain reaction; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma.

ISSN: 1471-2334